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ABSTRACT 
In Vitro Testing and Evaluation of Intraaortic 
and Extraaortic Balloon Counterpulsation Devices 
by Joseph V. Izzo 
The primary purpose of this project was to develop an 
in vitro environment in which the intraaortic and extra-
aortic balloon pumps could be tested and evaluated. This 
was done by modifying a mechanical heart simulator -- the 
pulse duplicator system -- to accomodate both devices, and 
developing a software system that could collect and process 
the data relevant to the operation of the two balloons. 
Both counterpulsation techniques were tested in the 
pulse duplicator where the aortic pressure and flow data 
were collected. The software system then processes the data 
to calculate all of the parameters affected by counterpulsa-
tion. 
While the results produced were not overly conclusive, 
there were some trends which were noted. While neither 
device demonstrated a more dominant effect on the mean 
systolic pressure, the extraaortic balloon appeared to have 
a more beneficial effect on the end diastolic pressure, 
stroke volume, and cardiac output. 
Since the pulse duplicator is a mechanical simulation 
of the human cardiac cycle, it does have its limitations. 
Future tests should be conducted with proper modifications 
made to the pulse duplicator. More extensive testing could 
reveal the extraaortic balloon pump to be a much more 
effective device for counterpulsation than the intraaortic 
balloon pump. 
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CHAPTER 1 
INTRODUCTION 
Counterpulsation has been used for several years as a means 
of aiding the failing heart in many patients. While 
extensive research had been conducted in the 60's and early 
70's to find the best device for counterpulsation, very 
little research has been done in this area since that time. 
Since research has been minimal, it is not surprising that 
one method of counterpulsation has been used in clinical 
situations more often than any other. 
The most predominant form of counterpulsation device in 
use today is the intraaortic balloon pump (IABP). While the 
intraaortic balloon pump has been used for many years, 
little has been done to increase its clinical effectiveness. 
As such, the medical research community may soon begin to 
reevaluate other methods of counterpulsation relative to the 
intraaortic balloon. One of the purposes of this thesis 
project has been to provide an in vitro environment where 
devices of this type can be tested and evaluated. By 
conducting in vitro testing of these devices, the researcher 
can determine if in vivo testing is warranted before the 
monetary investment in animal subjects, operating room time 
and staff have been made. 
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Although one purpose of this project was to develop the 
in vitro testing environment for various counterpulsation 
devices, the main focus of this project was the evaluation 
of the overall effectiveness of the intraaortic balloon pump 
versus the extraaortic balloon pump (EABP). Both devices 
were tested in a mechanical heart simulator -- the pulse 
duplicator system -- while pressure and flow data were 
collected and processed by a computer. The software system 
isolates a single wave cycle and determines several 
important pieces of information, including peak and mean 
pressures, stroke volume, and cardiac output among others. 
The software also generates a report containing all vital 
information related to the test. This data can then be 
compiled and analyzed accordingly. 
CHAPTER 2 
BACKGROUND AND HISTORY 
2.1 The Goal of Counterpulsation 
The basic purpose of counterpulsation is to assist the 
failing heart. When the heart is in failure, that simply 
means that the cardiac muscle must perform too much work for 
the amount of oxygen it is receiving via the coronary blood 
supply. There are several situations where these conditions 
exist, and they will be discussed in a later section. 
The description of heart failure stated above implies 
that any method of assistance must perform two primary 
functions. First, it must reduce the overall work done by 
the heart. Secondly, it must increase coronary perfusion, 
thereby increasing the flow of oxygen to the cardiac muscle. 
The work performed by the myocardium can be defined by 
the following equation: 
In this equation, W is the myocardial work, V is the volume 
of blood discharged during systole, P is the mean pressure 
that the heart works against (i.e. mean arterial systolic 
pressure), m is the mass of the ejected blood, and v is the 
average velocity of the ejected blood (1). It is obvious 
from this equation that when the mean pressure is reduced, 
so is the total work done by the heart. 
In order to meet the second requirement to assist the 
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failing heart, the amount of blood circulating through the 
coronary arteries must be increased. This could be done by 
reducing the amount of blood flowing to the body, but that 
would result in systemic ischemia and, perhaps, gangrene or 
other serious complications. Instead, the coronary 
perfusion must be increased by increasing the cardiac 
output. In other words, the total volume of blood ejected 
with each beat, or stroke volume (SV), must be increased. 
How this is done will be discussed in the next section. 
2.2 Physical Basis for Counterpulsation 
Counterpulsation can be defined as a balloon generated 
pressure pulse that occurs in a cycle counter to the normal 
cardiac pulse (2). From this definition it can be inferred 
that the peak pressure of the balloon generated wave will 
occur during the diastole phase of the cardiac cycle. 
Likewise, the minimum of the balloon pressure cycle will 
occur at the high pressure phase of the cardiac cycle 
(systole). 
The counterpulsation wave is generated by a balloon of 
a particular volume that is placed in some vicinity to the 
aorta. In the case of the intraaortic balloon pump, the 
device is placed inside the aorta in the descending arch 
(Figure 1). The extraaortic balloon is connected to the 
ascending arch via a cannula and is located outside of the 
patient's aorta (Figure 2). The wave is then generated by 
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Figure 1 Diagram Showing Proper Positioning 
of the IABP. (10) 
Figure 2 Diagram Showing Proper Positioning 
of the EABP. (9) 
inflating and deflating the balloon devices at specific 
times in the cardiac cycle. 
By inflating the aortic balloon at the end of diastole, 
just as the aortic valve closes, a volume of blood 
5 
6 
equivalent to the volume of the aortic balloon is displaced. 
By pushing blood out of the volume occupied by the balloon 
and into the aorta, the diastolic pressure within the aorta 
is increased. As such, the blood is pushed into the 
systemic and coronary circulations during the relaxation 
phase of the heart (2). 
At the beginning of the pumping phase of the heart, the 
balloon should be deflated. When the volume previously 
occupied by the balloon becomes vacant, it creates a small 
vacuum in that area. This causes a sharp reduction in the 
aortic pressure during the systolic phase. The net result 
at this point is that the amount of muscular force needed to 
pump blood out of the heart is reduced (2). This correlates 
directly with a reduction in myocardial work. 
2.3 Timing of the Aortic Balloon Pump 
Obviously, the timing of the balloon inflation and deflation 
points is extremely critical. There are four instances of 
improper timing of the aortic balloon. These, of course, 
are late inflation, early inflation, late deflation, and 
early deflation (2,3). The drawbacks to each of these 
scenarios will be discussed in this section. 
The first situation to be discussed is late inflation. 
If the balloon were inflated too late, much of the diastolic 
pressure augmentation would be lost. This reduces the 
pressure available to push blood into the coronary arteries. 
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As such, the oxygen supply to the heart muscle is not 
appreciably increased. 
On the other hand, if the balloon were to be inflated 
too early, this would cause a substantial increase in aortic 
pressure before the aortic valve closes. This scenario 
would result in a decreased stroke volume since the aortic 
valve would be forced to close before the ventricle could 
eject its maximum volume. 
While errors associated with inflation timing can diminish 
the effectiveness of the aortic balloon pump, so can errors 
in the deflation timing. For example, if the balloon were 
to be deflated late (i.e. balloon is still inflated during 
systole), the heart muscle would have to apply more pressure 
to push its volume past balloon. This would greatly 
increase the aortic systolic pressure which is contrary to 
what counterpulsation is trying to accomplish. Likewise, if 
the balloon is deflated too early, the vacuum caused by the 
balloon deflation would occur while the ventricle is still 
filling. This means that the aortic valve will open later 
than if optimum timing were used. As such, there will be 
little adjustment in the stroke volume of the heart, and 
thus the oxygen supply to the heart will not increase 
substantially. 
Obviously, the proper timing of the aortic balloon 
device is essential to its success in the clinical 
situation. Any deviation from the proper timing of the 
balloon can cause the assistance to the failing heart to be 
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diminished, if not hindered. In either case, the benefits 
to the patient are not what they should be. Therefore, 
careful consideration must be used when adjusting the timing 
of the aortic balloon pump. 
2.4 Clinical Uses of Counterpulsation 
As stated earlier, the primary purpose of counterpulsation 
is to assist the failing heart. Failure is determined by 
the imbalance of oxygen supplied to the heart and the oxygen 
required by the heart in order to function. Therefore, 
conditions where this imbalance is demonstrated are likely 
to indicate the need for some sort of counterpulsative 
assistance. 
While the general need for counterpulsation is the same 
in each case, the underlying cause of the problem can differ 
from one condition to another. The increased oxygen demand 
or diminished oxygen supply to the heart can be caused by a 
number of different factors. Some may be medical in origin, 
while others may result from mechanical defects (2). A few 
of these situations will be mentioned in this section so as 
to give an introduction into some areas where 
counterpulsation would be used. 
2.4.1 Medical Indications 
Some of the medical problems which may require counter-
pulsative assistance are cardiogenic shock after a 
myocardial infarction, septic shock, and unstable angina. 
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In each case, it is a medical, not mechanical, defect that 
is responsible for heart failure. 
In the case of a myocardial infarction, a portion of 
the cardiac muscle dies from oxygen starvation. The initial 
destruction of the myocardium usual comes from a narrowing 
or blockage of the cardiac circulation. Once a section of 
the heart muscle dies, it can no longer contract. As a 
result, the rest of the heart must increase its activity to 
compensate for the part lost to the infarction. In essence, 
the contractility of the heart is reduced. 
Cardiogenic shock can result after a myocardial 
infarction if the compensatory mechanisms of the body are 
unable to make up for the loss of myocardial tissue. 
Essentially, an avalanche effect occurs where more of the 
heart muscle is damaged until patient death ultimately 
occurs. If counterpulsation is employed at an early enough 
stage, the avalanche effect can be avoided with the hope 
that the bodies natural healing and compensatory mechanisms 
would become effective. 
Septic shock is similar to cardiogenic shock in that 
the heart muscle does not get the oxygen supply that it 
demands. However, septic shock is the result of an extreme 
reduction in systemic pressure. This type of shock is 
usually brought on by the presence of a toxin in the body 
which attacks the smooth muscle surrounding the blood 
vessels. The smooth muscle is paralyzed so that the blood 
vessels are dilated to an extreme amount. The net result is 
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to increase the volume in the body that the blood has to 
occupy. By keeping the volume of the fluid the same, and 
increasing the volume of the container, the systemic 
pressure drops dramatically. 
When the pressure of the system is reduced by a 
substantial amount, that in turn causes a lack of coronary 
circulation. When counterpulsation is used in this 
scenario, the pressure in the aorta is increased to the 
point where coronary perfusion, and thus coronary oxygen 
supply, is increased. Again, this technique is used so that 
the normal healing process of the body may deal with the 
underlying medical problem accordingly. 
The last medical indication for the use of counterpul-
sation that will be discussed is unstable angina. In a 
large number of cases, angina will be a predecessor to a 
myocardial infarction. In this case, the oxygen supply is 
reduced to the point where the patient will feel discomfort 
or pain, but the myocardium is not destroyed. 
For most people, prescription drugs (such as 
nitroglycerine) can help control angina, but in severe and 
unstable cases more drastic techniques must be used. Count-
erpulsation can be very effective in relieving the 
discomfort in some patients after only a few minutes of 
pumping. The main advantage here is that it allows more 
time for the physician to further analyze the patient's 
condition. 
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It should be reiterated here that these are only a few 
of the medical indications for counterpulsation use. There 
are several other conditions where oxygen supply to the 
heart is reduced, or oxygen demand is increased to a point 
where damage to the myocardium is the result. Again, this 
section was meant only to illustrate how a variety of 
different conditions can have a similar result that can be 
countermanded by the use of counterpulsation. 
2.4.2 Mechanical Insufficiencies 
As mentioned above, not only medical problems can lead to 
the insufficient oxygen delivery to the heart muscle. This 
same condition can result from mechanical defects of the 
heart as well. Two such conditions are valvular stenosis 
(narrowing of the valve opening) and valvular insufficiency. 
Valvular stenosis is described as the narrowing of the 
valve opening. By reducing the valve orifice, the pressure 
required to push blood through that opening is increased. 
When the aortic valve is stenotic, the left ventricle must 
contract harder and longer in order to eject the same volume 
as a normal valve. Similarly, when the mitral valve is 
stenotic, the volume entering the left ventricle is reduced, 
and there is a pressure build up in the right ventricle and 
pulmonary circuit. Both of these situations serve to 
decrease the efficiency of the heart. 
Counterpulsation is beneficial when valvular stenosis 
exists because it reduces the pressure in the aorta that the 
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ventricle is pumping against. As a result, the heart must 
do less work to move a comparable volume of blood than 
without the use of a balloon pump. 
The other type of mechanical defect is mitral valvular 
insufficiency. This situation results when a valve is 
unable to completely seal off the atrium from the ventricle 
when closed. Since the valve is not completely sealed, it 
allows some volume of blood to be ejected in the opposite 
direction of desired blood flow. Obviously, this decreases 
the stroke volume of the heart. 
By using counterpulsation in this instance, the 
pressure of the aorta is greatly reduced, thereby increasing 
the tendency for blood to flow towards it. This effect 
serves to increase the amount of blood flowing forward, 
despite the presence of mitral valvular insufficiency. 
2.5 History of Aortic Balloon Pumps 
The concept of counterpulsation is not a new idea. It was 
initially introduced in an article by Clauss and Birtwell in 
1961 (1). The device that they used consisted of an 
artificial ventricle attached to an actuator that simulated 
the volume changes of an actual ventricle. The artificial 
ventricle was located exterior to the body and was attached 
to the circulatory system via the femoral artery. 
The first design for an aortic balloon device came in 
1962. The first aortic balloon was an intraaortic type made 
by Moulopoulos and Kolff (6). The balloon used in these 
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cases was driven by a carbon dioxide pump and had only a 
20 cc displacement volume. Most of the initial tests 
performed by this group were in a mock circulatory system, 
on dogs (deceased and living), and human cadavers. The 
initial tests showed that cardiac output could be increased, 
and that the end diastolic pressure (and thus, the cardiac 
work) could be reduced with the use of the aortic balloon. 
However, the later clinical tests were not as successful. 
The intraaortic balloon pump still had several more years of 
research and improvements to undergo. 
Figure 3 The Dynamic Aortic Patch. (5) 
In 1972, Kantrowitz proposed a device which was similar 
to the intraaortic balloon pump in function, but was meant 
to serve as a permanent assisting device (5). This device 
was known as the dynamic aortic patch (Figure 3). It was 
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basically constructed as an ellipsoidal balloon which gets 
sewn into the wall of the descending aorta. As such, when 
it is inflated, its volume expands from one side of the 
aorta across to the other, rather than from the center of 
the aorta outwards in all directions. 
The first clinical test of the aortic patch on a human 
showed that the device could be effective. Prior to this 
test, many patients had died from emboli formation. In the 
case reported by Kantrowitz in 1972, the dynamic aortic 
patch resisted the formation of thromboemboli. Unfortunate-
ly, his patient died from a massive infection 96 days after 
implantation of the aortic patch. 
Figure 4 Diagram of the Single and Dual 
Chambered IABP's. (7) 
Also in 1972, the idea of a dual chambered balloon was 
introduced (Figure 4). Bregman and Goetz designed a balloon 
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that had two sections (7). It had the long, cylindrical 
segment which looked and functioned exactly like the 
standard intraaortic balloon. However, attached to the 
distal portion of the balloon was smaller balloon. The 
smaller balloon had a larger diameter than the larger 
balloon. The purpose was to inflate the smaller balloon 
before the larger balloon. The smaller balloon would then 
obstruct the flow of blood to the systemic circulation. As 
such, most of the ejected blood volume from the heart would 
be forced into the coronary circulation. 
While the double chambered intraaortic balloon did not 
become very popular, its design introduced the use of an 
external safety chamber for the pumping mechanism. (Figure 
5) The safety chamber is used to regulate the volume of gas 
used to inflate the balloon with each cycle. It consists of 
a rigid, plastic cylinder placed outside of the body. 
Inside the rigid cylinder is a balloon which has the same 
volume as the aortic balloon. The system is primed so that 
Figure 5 Schematic Diagram of A Rigid 
Safety Chamber. (7) 
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when the aortic balloon is deflated, the safety balloon is 
completely inflated. 
By increasing the pressure in the safety chamber, the 
balloon contained in the safety chamber is deflated. As a 
result, the full volume of the safety balloon is pushed into 
the aortic balloon. Conversely, by reducing the pressure in 
the safety chamber, the safety balloon can draw gas out of 
the aortic balloon, causing it to deflate. 
The safety chamber has several beneficial properties. 
First, it can regulate the amount of gas used to inflate the 
aortic balloon. As such, the likelihood of over or under 
inflation of the balloon is reduced. Similarly, if the 
aortic balloon should rupture for some reason, only a 
limited volume of gas would be introduced into the patients 
blood stream. Due to its beneficial design, the external 
safety chamber is still used on many modern intraaortic 
balloon control units. 
In the early 1960's, several groups experimented with 
devices that would deliver counterpulsation from a position 
that was external to the aorta. The first of these devices 
was described in 1963 by Nose and Kantrowitz (8). This 
device served as an auxiliary left ventricle that was pumped 
by an external controlling unit (Figure 6). The auxiliary 
ventricle was connected to the ascending aorta on one side, 
and the descending aorta on the other. In some cases, the 
aorta was actually severed and sealed at the arch, just 
proximal to the coronary arteries. 
Figure 6 The Auxiliary Ventricle. (8) 
Over the next ten years, Kantrowitz and Nose continued 
to research and develop the auxiliary ventricle. Many of 
the clinical studies did not have promising results. Most 
of the dogs that had the device implanted died within two 
weeks. In the last clinical case, the patient only survived 
for 12 days. The autopsy of this subject showed that there 
had been extensive damage due to emboli formation. 
It was not until several years later that anyone 
produced positive results with an extraaortic counter-
pulsation device. In 1981, Gabbay proposed the device which 
is currently called the extraaortic balloon pump (9). 
It consisted of a rigid external housing with a balloon 
inside. The balloon was inflated and deflated by applying 
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an alternating positive/negative pressure to the balloon 
inside the housing. When a negative pressure was applied 
the balloon would inflate, thereby drawing blood out of the 
aorta. The opposite would occur when a positive pressure 
was applied. 
This device differed from the auxiliary ventricle in 
that it was open to the circulatory system at one end only. 
As such, it was hoped that any emboli formation would be 
limited to the inside of the device only. Should extensive 
emboli formation take place, the device could be removed 
(emboli and all) and replaced with a new one. 
The early animal test results looked promising. In 
most cases, it outperformed the intraaortic balloon in 
systolic reduction, diastolic augmentation, and cardiac 
output increase. Despite its efficiency, the extraaortic 
balloon pump did not become overly popular because of the 
methods and difficulties of inserting it via a very invasive 
surgical procedure. 
In 1983, Gabbay published another article dealing with 
a redesigned extraaortic balloon that is commonly called the 
EABP II (10). In this case, the balloon inside the rigid 
shell was replaced with a diaphragm that was stretched 
across the shell. In this position, the balloon (diaphragm) 
was inflated from one side only. Through this construction, 
the overall size of the extraaortic balloon pump was 
decreased while its efficiency was increased. It was a 
balloon of this type that was tested, along with the 
intraaortic balloon, for this project. 
Figure 7 Diagram of the EABP II. (10) 
As can be seen from this section, the overall idea of 
counterpulsation to assist the failing heart has been around 
for many years. Due to the initial success and easy use of 
the intraaortic balloon pump, it gained favor in the medical 
community. As such, most efforts to improve counterpulsa-
tion went into improving the intraaortic balloon rather than 
developing the extraaortic balloon. One of the primary 
purposes of this thesis is to help rejuvenate an interest in 
the research and development of the extraaortic balloon 
pump. 
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CHAPTER 3 
METHODS AND MATERIALS 
3.1 The Pulse Duplicator System 
The pulse duplicator system (PDS) is a device used as a 
mechanical simulator for the cardiac cycle. It was 
developed over several years at the Cardiothoracic Research 
Laboratory at the University of Medicine and Dentistry of 
New Jersey (UMDNJ). Over the years, many individuals have 
contributed to the pulse duplicator project. 
The primary function of the pulse duplicator system to 
date has been the hemodynamic testing of prosthetic heart 
valves. As such, it was designed so that pressure and flow 
data could be measured at the mitral and aortic positions. 
Since the balloon pumps are located in or near the aorta, it 
was this position that was used in their testing. 
The overall idea behind the construction and architec-
ture of the pulse duplicator is relatively simple. It 
consists of several plexiglass chambers and tubes which are 
meant to represent the left atrium, left ventricle, and 
aorta. Another chamber is used to represent the compliance 
of the aorta and the systemic circulation. The peripheral 
resistance of the system is generated by the serial combina-
tion of a filter and a column of water. Holes were drilled 
in the plexiglass where pressure taps were desired. For 
this project, one pressure tap was used and it was located 
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slightly beyond the aortic valve. A schematic diagram 
showing the general positions of each piece can be seen in 
Figure 8. 
Figure 8 Schematic of Pulse Duplicator System. 
The pulse duplicator is also equipped with a piston 
pump which is used to generate the pumping action of the 
simulated heart. The stroke volume can be adjusted by 
changing the length of the piston displacement. The pump 
rate can be adjusted by changing the speed of the motor. By 
doing so, the simulated heart rate can be set to the desired 
level. Both of these factors were adjusted during the 
testing procedures. 
The pulse duplicator system is set up to collect 
pressure and flow data via a computer. As such, the pulse 
duplicator is equipped with two electromagnetic flow probes 
that are permanently mounted on the device. One probe is 
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used to measure the flow through the mitral valve, while the 
other is arranged to measure flow through the aortic valve. 
For the purpose of this project, the aortic flow probe was 
used. 
The pressure data for the aortic balloon testing is 
collected from a pressure transducer located just beyond the 
aortic valve. The pressure measured at this point is read 
into the Kontron aortic balloon control unit (to be 
discussed later) where it is used for the timing trigger of 
the balloon. This information then gets passed to the 
computer where it is stored on disk. 
3.2 The Computer and Data Acquisition Hardware 
The data collection system for this project consists of two 
major components -- the computer, and the analog to digital 
data acquisition card. The pulse duplicator system was 
coupled with a computer many years ago to fascilitate data 
collection and processing speed. Over the years, the system 
has been upgraded to its present condition. Both of the 
components that were used for this project will be discussed 
in this section. 
The computer used for the aortic balloon pump project, 
as well as other projects in the Cardiothoracic Research 
Laboratory, is based on an 80386 IBM compatible computer. 
The computer is also equipped with a floating point math 
coprocessor to speed up the data processing portion of the 
software system. The computer is attached to a Super VGA 
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color monitor for a high resolution graphic representation 
of wave forms, and a Hewlett Packard Laser Jet III printer 
for hardcopy print outs of test results. 
The computer is also equipped with a Keithley/MetraByte 
DAS8/PGA data acquisition card (13). The analog to digital 
converter on the card is a 12 bit, successive approximation 
converter with an average conversion time of 15 milli-
seconds. While only two of the channels were used for this 
project, the presence of 8 channels allows for the easy 
expansion of this project in the future. 
The card also incorporates into its design three 
programmable counters and a one megahertz crystal 
oscillator. When these two components are coupled together, 
they can generate a suitable square wave to trigger 
interrupt driven data acquisition. As such, an equal time 
interval between data points can be assured at all times. 
Another convenient characteristic of the Keithley/Met-
raByte data acquisition board is that it comes with several 
software library files which make initialization and data 
collection with the board very easy. This eliminated the 
need for tedious, and difficult software coding. 
Overall, many of the components of the computer 
hardware system were chosen because of their speed, 
reliability, and ability to be upgraded. The system can 
easily be repaired or upgraded by replacing only one portion 
of the system. This eliminated the need to purchase a new 
system whenever one component is to be changed. 
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3.3 The Computer Software System 
The computer software system for the aortic balloon testing 
project was developed in the Cardiothoracic Research 
Laboratory at UMDNJ specifically for use during this project 
(18). Under the supervision of Dr. Gabbay (UMDNJ) and Dr. 
Mayott (NJIT), the system was designed to interface with the 
existing pulse duplicator system, collect the relevant 
pressure and flow data, and to process that information 
accordingly. The program was also written in a modular type 
of format so it could easily be debugged and modified. 
While most of the program was written for this project, 
some of the subroutines were written by Mr. John Andrews of 
NJIT who wrote the software for the testing of heart valve 
prosthesis in the pulse duplicator system. The routines 
which were borrowed from Mr. Andrews' program were mainly 
for cosmetic purposes. Since both systems now have the same 
look and feel, a user who is familiar with one system may 
use the other without much difficulty. 
The software system was coded using Microsoft 
QuickBASIC and the QuickBASIC library files that accompanied 
the Keithley/MetraByte data acquisition card. The library 
files made programming the data acquisition board very 
simple. It allowed certain functions to be called by 
setting the values of a few variables and executing a CALL 
statement. 
The workings of the program are very straight forward. 
It firsts collects relevant data about the test to be 
25 
performed, including the date, balloon size, and test 
number. This information is stored so it can be recalled at 
a later date. 
The computer also prompts the user through a 
calibration sequence. A water manometer is used in 
calibrating the pressure transducer, while two reference 
voltages are used to calibrate the electromagnetic flow 
meter. In each case, a linear interpolation technique is 
employed to determine the appropriate calibration factor for 
each instrument. The data collected in this segment is 
stored in a special calibration file to be referenced for 
use in other portions of the program. 
Much of the remainder of the program is dedicated to 
the collection, storage, and processing of the test data. 
Once the program is instructed to start collecting data, it 
automatically collects 2.75 complete cycles of the pressure 
and flow wave forms. It then isolates a single wave of 
each, aligns them properly, and continues to process them. 
The data for each wave form is also stored in its own data 
file so it may be recalled at a later time. 
There are several pieces of information which are 
calculated by the software system. All of the parameters 
which are either measured or calculated by the computer 
program are: 
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o Peak Systolic Pressure (PSP) 
o Peak Diastolic Pressure (PDP) 
o End Diastolic Pressure (EDP) 
o Mean Arterial Systolic Pressure (MASP) 
o Mean Arterial Diastolic Pressure (MADP) 
o Mean Arterial Pressure (MAP) 
o Heart Rate (HR) 
o Stroke Volume (SV) 
o Cardiac Output (CO) 
These are the predominant parameters that can be measured to 
document the effectiveness of the aortic balloon pump. 
Each of these parameters is found by either direct 
measurement or by calculation. The peak systolic and 
diastolic pressures are the values where the pressure curve 
has zero slope. The end diastolic pressure is simply the 
minimum value of the pressure curve. On the other hand, the 
mean arterial pressures are calculated by integrating under 
the appropriate portions of the pressure curve. These are 
not arithmetic means, but area means (i.e. the total area 
bounded by the mean pressure and the pressure wave form is 
zero). In a similar fashion, the stroke volume is found by 
integrating under the flow curve. The cardiac output is 
simply the stroke volume multiplied by the heart rate. Once 
all of these steps and calculations have been performed, the 
computer moves on the next stage. 
The final section of the program generates a report 
which is printed out on the laser printer. The report 
presents all of the data mentioned above, including the test 
date, balloon type and size. The report also contains a 
visual representation of the actual flow and pressure wave 
forms. Since all the data for each test is stored at one 
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point or another, a duplicate report can be generated at any 
time by supplying only the test number that is to be 
reviewed. 
In general, the system was designed to be easy to use, 
and also to allow for the recalling of the various data. As 
such, the data is stored in two places (a print out, and on 
the computer) and makes the data storage easier. 
3.4 The IABP/EABP Control Unit 
As mentioned in an earlier section, the timing of the aortic 
balloon is extremely important. As such, it must be coupled 
with a driving unit which can control the inflation and 
deflation of the device. There are many different types of 
machines that are available to perform this function. For 
this project, a Kontron Air Ambulance Transport Intraaortic 
Balloon Pump System was used (2). 
The Kontron control unit is a very versatile device for 
controlling the intraaortic balloon pump. It is equipped 
with a safety chamber as described earlier to inflate and 
deflate the aortic balloon. The balloon itself is filled 
with helium gas because it is easier to move through small 
tubes, and is less likely to form emboli that can block 
capillaries. It contains a small helium tank for this 
purpose. 
The control unit is also equipped with a CRT screen to 
show the user several different pieces of information. The 
CRT constantly displays three wave forms -- the patient's 
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ECG wave, either the arterial pressure wave or an auxiliary 
pressure wave, and the balloon pressure wave. The control 
unit also displays several other parameters, including the 
peak diastolic pressure, the peak systolic pressure, the end 
diastolic pressure, the mean arterial pressure and the heart 
rate. 
Surrounding the CRT screen are a set of "soft keys" 
which are used to pull up menus and perform various 
functions. The menus which can be selected are The 
Operations Menu, the Calibration Menu, the Alarms Menu, and 
the Recorder Menu. The Operational Menu allows the user to 
set the balloon inflation volume, the pump ratio, and the 
trigger pattern. From the Calibration Menu, the pressure 
transducer is calibrated, and the display ranges can be set. 
The Alarms Menu allows the user to disable any alarms that 
may cause the system to shut down automatically. Finally, 
the Recorder Menu is where the parameters for the optional 
strip chart recorder are set, including which waves (up to 
two) will be displayed, and how fast the recorder paper will 
move. All of these functions are explained in more detail 
in the operations manual for this particular device. 
On the front panel of the control unit, there are also 
a set of analog inputs and analog outputs. The inputs allow 
signals to be entered from other devices, such as an 
external ECG monitor, or external pressure signals. The 
analog outputs allow the signals which are obtained by the 
control unit to be output to another device. For this 
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project, the arterial pressure wave was read by the control 
unit's pressure transducer and is then sent to the computer 
via these output plugs. 
One of the reasons that this particular unit is so 
versatile is because it can trigger the balloon inflation/ 
deflation from several different inputs including electro-
cardiogram (ECG), arterial pressure wave, or an internal 
trigger source. The availability of several trigger sources 
is very beneficial in a clinical situation. However, since 
this project dealt with an in vitro testing environment, 
only the arterial pressure wave could be used for triggering 
the balloon operation. 
While the control unit controls the timing of the 
balloon inflation/deflation, it does not perform the timing 
in an optimal fashion. Therefore, the control unit is 
equipped with two controls knobs which allow the user to 
adjust the balloon inflation and deflation timing. As such, 
the operator can fine tune the balloon inflation and 
deflation points. 
Overall, the intraaortic balloon pump control unit, 
manufactured by Kontron Instruments, is a typical example of 
the various balloon pump control units that are commercially 
available. Many of the features described above are also 
present on devices manufactured by other medical device 
companies. 
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3.5 The Intraaortic and Extraaortic Balloons 
The design of the intraaortic and extraaortic balloons are 
relatively simple. This section will briefly describe the 
each of these devices. 
The first device that will be described is the intra-
aortic balloon. The actual balloon is a long, slender 
cylinder of thin polyurethane. The balloon is placed so it 
covers the last several inches of a semiflexible catheter. 
The catheter is used to carry the inflating gas (helium) 
from the control pump unit to the balloon. The covered 
portion of the catheter contains several holes so the 
inflation/deflation of the balloon is uniform, rather than 
from one end to the other. 
The intraaortic balloons can come in a number of 
different volumes. For this project, a 40 cc balloon was 
used. The dimensions of the balloon all depend on the 
maximum volume of the balloon. The diameter is limited 
since the balloon should not completely occlude the artery 
when it is inflated. The balloon that was used for this 
project had a length of approximately 26 centimeters and a 
diameter of a little less than 1.5 centimeters. 
The construction of the extraaortic balloon is quite 
different than the intraaortic balloon. The extraaortic 
balloon which was tested for this project was the EABP II 
design which was in the previous chapter. It has a rigid, 
outer shell made of polyurethane with the flexible diaphragm 
stretched across the center of the shell. This balloon had 
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a shell volume of 60 cc, but the diaphragm was shaped so it 
could only displace 40 cc. 
The extraaortic balloon has an advantage over the 
intraaortic balloon when it comes to size limitations. 
While the diameter of the intraaortic balloon should not he 
equal to or greater than the diameter of the aorta, the size 
and shape of the extraaortic device do not have such 
limitations. Since the extraaortic balloon is placed 
outside of the circulatory system, the only limitations 
would be placed on the size of the catheter that was used. 
As is described in this section, the design and 
construction of both devices, while very different, are 
relatively simple. For the most part, each device is just a 
set of various plastic components that are assembled in the 
required fashion. 
3.6 Method of Testing 
The testing procedure both of these devices was relatively 
straight forward. The goal was to evaluate the intraaortic 
balloon and the extraaortic balloon versus a no balloon 
(control) situation. A protocol was devised to test both 
devices at several pump rates and a variety of stroke 
volumes. The object was to simulate failure in the system, 
where failure is defined as a cardiac output below four 
liters per minute. A summary of the testing procedure is as 
follows: 
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1) Test system with: No Balloon (Control Group) 
Intraaortic Balloon Pump 
Extraaortic Balloon Pump 
2) Heart Rates: 	 75, 85, 95, 105, and 115 
(each device) beats per minute 
3) Stroke Volumes: 35, 40, and 50 ml per beat 
(each device) 
This testing procedure resulted in a total of 45 
individual tests being performed. The software system 
generated a report containing values for several parameters 
after each test run. The parameters which are the main 
focus of this study are the mean arterial systolic pressure 
(MASP), the mean arterial diastolic pressure (MADP), the 
cardiac output (CO), and the end diastolic pressure (EDP). 
A discussion of the data that was obtained comes in the next 
chapter. 
CHAPTER 4 
SUMMARY OF RESULTS 
There were four complete sets of data that were collected 
during the course of this project. Each data set consisted 
of test runs at three different stroke volumes, and 5 
different heart rates. One set of data was collected with 
the intraaortic balloon pump and another set with the 
extraaortic balloon pump. There were two complete sets of 
data for the control (no balloon) situation -- one set for 
each balloon pump. 
The initial objective of this project was to evaluate 
how the aortic balloon pumps would affect the failing heart. 
For this project, "failure" was defined as having an unas-
sisted cardiac output below four liters per minute. Due to 
limitations of the pulse duplicator system, the number of 
points that actually met this criterion was less than the 
total number of points collected. 
The data that was collected will be analyzed and 
presented in a number of different ways in order to find any 
trends that may exists. First, the average data for all 
points will be described. This data will be compared to the 
average data for points that correspond to failure only, 
where failure is defined as a condition where the unassisted 
cardiac output is below four liters per minute. Then, the 
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major parameters will be shown versus other parameters such 
as heart rate and unassisted cardiac output. 
It was also mentioned in the previous chapter that 
there were five parameters which were the primary focus of 
this project. They are the mean arterial systolic pressure, 
the mean arterial diastolic pressure, the end diastolic 
pressure, the stroke volume, and the cardiac output. The 
effect of the balloon pumps on these parameters as described 
above will be discussed throughout the remainder of this 
chapter. 
4.1 Mean Data 
First, the effects of counterpulsation on the three pressure 
parameters will be discussed. It is expect that there will 
be a reduction in both the mean arterial systolic pressure 
and the end diastolic pressure. It is also expected that 
there will be an increase in the mean arterial diastolic 
pressure. In fact, all of these occurred during the in 
vitro testing that was performed. 
Figure 9 contains a graph showing the mean effects of 
the counterpulsation devices on the three pressure 
parameters. The information for this graph comes from the 
arithmetic average of all data points that were collected. 
Figure 10 shows the same parameters, but using only those 
points that occurred during failure (unassisted cardiac 
output less than 4 L/min) were used in its construction. 
Figure 9 Mean Pressure Data (All Data) 
Figure 10 Mean Pressure Data (Failure Only) 
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mean arterial systolic or diastolic pressures. On the other 
hand, it seems that the extraaortic balloon had an increased 
effect on the end diastolic pressure when the heart was in 
simulated failure. 
Figure 11 Mean Cardiac Output Data 
The effects of the counterpulsative devices on the 
cardiac output will now be examined. Figure 11 shows the 
effect on cardiac output for all data points and the data 
points which correspond to failure only. Like before, these 
points are the arithmetic average of the points that are 
specified. From this figure, it is obvious to see that the 
extraaortic balloon pump consistently provides a cardiac 
output that is 1.2 L/min more than the intraaortic balloon, 
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and 3.2 L/min higher than the control situation. It should 
also be noted that the mean data from the failure points is 
consistently 0.7 L/min less than the data obtained from all 
of the data points. 
The information presented in Figure 11 illustrates two 
noticeable trends. First, cardiac output of the extraaortic 
balloon pump shows a marked increase over the intraaortic 
balloon pump. Secondly, it can be seen that the value of 
the cardiac output is related to the level of failure that 
is encountered. This second trend is not unexpected since 
the definition of failure is based on a low value for the 
cardiac output. By eliminating points that were outside of 
the failure limits, several of the points of higher cardiac 
output were eliminated as well. 
Lastly, the mean values of the stroke volume will be 
discussed. Figure 12 contains this information in failure 
only, and from all points obtained. As with the cardiac 
output data, it should be noted that the extraaortic balloon 
produces as larger increase in stroke volume (about 34 ml 
above control) than the intraaortic balloon pump (around 22 
ml above control). The net effect is a 12 milliliter per 
beat advantage for the extraaortic balloon over the intra-
aortic balloon. 
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Figure 12 Mean Stroke Volume Data 
4.2 Parameters Versus Heart Rate 
This section will present the same five parameters listed 
above, but as a function of heart rate rather than the 
overall mean data. By presenting the data in this format, 
additional trends may become visible. 
Table 1 contains the values of the mean systolic 
pressure as related to heart rate. The information for the 
mean arterial diastolic and end diastolic pressures can be 
seen in Tables 2 and 3 respectively. A series of 
corresponding graphs related to these tables can be seen in 
Appendix B. 
Table 1 
Mean Arterial Systolic Pressure vs. Heart Rate 
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HR 
75 
Control 
(mmHg) 
45.4 
85 48.8 
95 50.0 
105 47.6 
115 48.8 
EABP 
(fig) 
IABP 
(fig) 
35.2 37.9 
37.5 34.6 
40.4 38.1 
40.6 39.7 
43.2 42.0 
Table 2 
Mean Arterial Diastolic Pressure vs. Heart Rate 
HR 
75 
Control 
(mmHg) 
33.2 
85 36.8 
95 38.4 
105 38.9 
115 39.7 
EABP 
(mmHg) 
IABP 
(mmHg) 
46.6 48.9 
49.2 49.3 
45.8 50.1 
42.9 50.9 
42.8 50.6 
Table 3 
End Diastolic Pressure vs. Heat. Rate 
HR Control 
( 	 g) 
EABP 
(mmHg) 
IABP 
(mmHg) 
75 27.7 5.8 10.3 
85 30.6 13.8 16.4 
95 32.1 14.9 18.2 
105 33.2 16.8 22.1 
115 34.8 20.5 24.2 
The data in these tables demonstrates that there is not 
a substantial difference between the effect of the intra-
aortic balloon and the extraaortic balloon pump on the 
systolic pressure. Both seem to reduce the systolic 
pressure by a similar amount. However, there does seem to 
be a trend where the mean arterial systolic pressure 
increases as the heart rate increases. 
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As for the effect of each device on the mean arterial 
diastolic pressure, it appears that again, the intraaortic 
balloon produces a higher mean diastolic pressure than the 
extraaortic balloon pump, especially at higher heart rates. 
The numbers show that the intraaortic balloon maintains an 
average advantage of four millimeters of mercury over the 
extraaortic balloon. Also, it seems that the mean diastolic 
pressure drops down as heart rate increases for the 
extraaortic balloon while the pressure remains relatively 
constant for the intraaortic balloon. 
It can also be seen from Table 3 that the extraaortic 
balloon pump still shows a larger end diastolic pressure 
reduction than the intraaortic balloon pump. There also 
seems to be a trend where the end diastolic pressure 
increases with an increase in heart rate. This information 
is not remarkably different from the mean data that was 
presented in the previous section. 
Table 4 contains the stroke volume data related to 
heart rate, while Table 5 shows the cardiac output data. 
The results here are very similar to those indicated by the 
mean data that was discussed above. It is easy to see from 
these tables that the extraaortic balloon pump increases the 
stroke volume by an average of 12 milliliters above that of 
the intraaortic balloon. Similarly, the extraaortic balloon 
increases the cardiac output by one liter per minute above 
the intraaortic balloon. In both cases, this is a 
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substantial advantage of the extraaortic balloon over the 
intraaortic balloon pump. 
Table 4 
Stoke Volume vs. Heart Rate 
HR Control 
(ml) 
EABP 
(ml) 
IABP 
(ml) 
75 41.1 83.1 61.8 
85 43.0 73.9 63.2 
95 44.2 75.6 68.2 
105 40.4 75.9 59.0 
115 43.0 67.8 64.7 
Table 5 
Cardiac Output vs. Heart Rate 
HR Control 
(L/min) 
EABP 
(L/min) 
IABP 
(L/min) 
75 3.1 6.5 4.6 
85 3.7 6.4 5.4 
95 4.2 7.2 6.5 
105 4.3 8.0 6.2 
115 4.9 7.8 7.4 
4.3 Parameters Versus Unassisted Cardiac Output 
As was seen in Section 4.1, some parameters seemed to be 
more profoundly effected if only those points that were 
considered failure were used in their evaluation. Since the 
ultimate goal of this project was to see how the counterpul-
sation devices performed under simulated failure conditions, 
only these points will be presented in this section. 
Figures 13, 14, and 15 all show plots of the three 
measured pressures versus the unassisted cardiac output of 
the heart. Since the definition of failure used for this 
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project was based only on the unassisted cardiac output, 
these graphs show how the system pressures were effected by 
the level of failure that was experienced by the system. 
Figure 13 Mean Arterial Systolic Pressure 
Versus Unassisted Cardiac Output 
This information indicates that neither device produces 
a more beneficial effect on the mean arterial systolic 
pressure. In fact, these graphs shown them to be almost 
identical for each cardiac output. 
However, the graph showing the mean arterial diastolic 
pressure shows an interesting trend. While the intraaortic 
balloon shows a relatively constant pressure, the extraaor-
tic balloon seems to cause an increase in diastolic pressure 
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Figure 14 Mean Arterial Diastolic Pressure 
Versus Unassisted Cardiac Output 
as the cardiac output decreases. This leads to the notion 
that the extraaortic balloon may produce a higher mean 
diastolic pressure, and thus coronary perfusion pressure, as 
the level of failure increases. 
A look at the plot for end diastolic pressure does not 
seem to indicate any new trends. The end diastolic pressure 
produced by the extraaortic balloon is substantially lower 
than the pressure produced by the intraaortic balloon. The 
plot also shows that the extraaortic balloon seems to have a 
more prominent effect on this parameter when the level of 
failure increases. 
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Figure 15 End Diastolic Pressure 
Versus Unassisted Cardiac Output 
The final parameter that will be examined in this 
section is the measured cardiac output with respect to the 
unassisted cardiac output. This information can be seen in 
Figure 16. It should be noted that the extraaortic balloon 
produces a cardiac output that is either the same as, or 
higher than the cardiac output generated when the 
intraaortic balloon pump is used. However, the points from 
the extraaortic balloon are quite scattered on the graph. 
Because of this scattering of data points, it is very 
difficult to interpret any trends that may exist on this 
graph. As a result, further testing would have to be done 
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Figure 16 Actual Cardiac Output Versus 
Unassisted Cardiac Output 
in order to gain any other conclusive evidence from this 
relationship. 
CHAPTER 5 
CONCLUSIONS 
At this point, it should be reiterated that one of the 
primary purposes behind this project was to demonstrate that 
research behind alternative counterpulsation devices --
namely the extraaortic balloon pump -- is an avenue that 
should not be abandoned. While the intraaortic balloon pump 
has become the standard for counterpulsation, it has been 
shown that the intraaortic and extraaortic balloons effect 
certain physiological parameters to different degrees. 
One of the goals of counterpulsation is to cause a 
reduction in the arterial systolic pressure. The test 
results from this project consistently showed that there is 
very little difference between the intraaortic balloon and 
extraaortic balloon when it comes to the reduction of the 
systolic pressure. Both devices appeared to have generated 
comparable systolic reduction in all levels of failure. 
It was noted in the previous chapter that the 
intraaortic balloon tended to produce a higher mean arterial 
diastolic pressure than the extraaortic balloon pump. 
However, since this is an in vitro study, these numbers may 
be misleading. The function and position of the intraaortic 
balloon is such that it will cause blood to flow both 
forward, through the systemic circulation, and backwards, 
through the coronary circulation. The pulse duplicator 
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system is not equipped with a coronary circulation circuit 
upstream from the balloon placement. This means that the 
blood flow in the reverse direction has no path to follow. 
As such, there would be a slight build up in pressure behind 
the intraaortic balloon in the in vitro system that probably 
would not be seen in a physiological system. 
Another parameter that is effected by the balloons is 
the end diastolic pressure. The data that was collected 
indicated that the extraaortic balloon caused a larger 
reduction in end diastolic pressure than the intraaortic 
balloon. Physiologically, this means that the heart would 
experience a shorter isovolumetric contraction phase. In 
the testing environment, it would indicate that the piston 
pump had to do less work. The pulse duplicator pump 
operates at a constant velocity and constant stroke volume. 
By lowering the end diastolic pressure in the aorta, the 
piston pump experiences a lower resistance pressure through 
its displacement. Therefore, it would seem likely that the 
larger pressure reduction seen in the in vitro system might 
be observed in an in vivo system as well. 
Finally, it should be noted that the extraaortic 
balloon pump of the same displacement volume produced a much 
higher cardiac output and stroke volume than the intraaortic 
balloon. This indicates that the extraaortic balloon has a 
certain advantage over the intraaortic balloon in this area. 
By increasing the fluid ejected from the heart, the 
oxygenated blood supply to the myocardium is being increased 
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as well. This is a highly advantageous and desirable 
situation in the case of a failing heart. 
From the data obtained in this study, it cannot be 
decided conclusively which device is best for supplying 
counterpulsation. Neither has the advantage in mean 
systolic reduction. However, the intraaortic balloon 
appears to have the advantage in diastolic pressure 
augmentation, while the extraaortic balloon seems to be 
superior when comparing the end diastolic pressure and the 
fluid output of the heart. 
Although this study has shown neither device to be 
exceptionally superior over the other, it would seem to 
indicate that further study is required. Future studies may 
include a model of the coronary circulation to see how the 
pressure and flow data will be affected. Also, the piston 
pump could be modified to accommodate even lower stroke 
volumes so that tests could be conducted in more severe 
levels of failure. Another way of improving the testing 
procedure would be to use a flexible piece of tubing for the 
aorta. Since the aorta for this project was made of rigid 
plexiglass, any localized effects of its compliance was 
lost. Of course, in vivo studies should be conducted in the 
near future as well. 
While there are still many areas of study that should 
be addressed in the future, this work indicates that further 
studies are warranted. Scientists and engineers involved in 
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the medical field should always look to improve the quality 
and efficiency of existing techniques. The intraaortic 
balloon pump has shown very little increase in efficiency 
and effectiveness over the past several years. The 
extraaortic balloon may very well be the next level in 
counterpulsative technology. 
APPENDIX A 
Tables of Collected Data 
Table 6 Stroke Volume = 35 ml 
Data 
Group 
HR 
(bt/min) 
MASP 
(mmHg) 
MADP 
(mmHg) 
EDP 
(mmHg) 
SV 
(ml/bt) 
CO 
(L/min)  
Control 73.9 46.8 29.3 26.1 35.7 2.6 
(EABP) 84.5 46.7 33.8 26.0 38.6 3.3 
96.2 52.4 35.3 27.9 37.2 3.6 
107.1 41.9 35.4 28.9 31.9 3.4 
117.2 48.1 40.5 35.0 38.4 4.5 
Control 78.1 43.7 33.8 28.8 32.2 2.5 
(IABP) 87.0 44.8 35.6 30.1 34.2 3.0 
94.6 49.7 41.0 35.8 30.7 2.8 
104.9 49.7 40.8 36.7 32.2 3.4 
117.2 50.3 40.9 37.8 32.9 3.9 
EABP 75.4 33.5 49.5 5.8 66.2 5.0 
86.7 31.6 49.0 4.5 79.7 6.9 
96.8 35.3 43.0 9.1 70.7 6.8 
107.5 37.6 39.2 12.0 55.2 5.9 
114.9 42.9 42.7 17.0 57.6 6.6 
IABP 73.9 33.5 49.5 10.8 66.2 5.0 
85.0 31.6 49.2 19.1 68.7 5.8 
96.8 37.6 50.9 24.9 60.4 5.8 
104.5 39.5 49.9 26.8 49.0 5.1 
114.1 44.4 49.4 28.4 65.9 7.5 
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Table 7 Stroke Volume = 40 ml 
Data 
Group 
HR 
(bt/min) 
MASP 
(mmHg) 
MADP 
(mmHg) 
EDP 
(mmHg) 
SV 
(ml/bt) 
CO 
(L/min)  
Control 1 75.6 42.3 31.9 26.1 39.4 3.0 
(EABP) 85.5 51.3 40.0 34.7 42.5 3.6 
95.8 45.5 38.7 31.2 45.4 4.4 
105.6 43.2 35.6 28.9 35.6 3.8 
112.8 44.0 35.2 29.3 40.0 4.5 
Control 2 76.3 47.8 35.9 30.5 39.6 3.0 
(IABP) 85.7 48.0 37.3 31.3 39.3 3.4 
94.9 49.8 37.7 31.8 43.0 4.1 
105.6 47.9 37.2 32.9 39.2 4.1 
115.4 47.3 36.6 33.1 47.9 5.5 
EABP 77.5 34.6 45.1 5.9 86.7 6.7 
88.2 37.9 50.1 20.6 57.7 5.1 
94.6 40.2 45.0 12.1 65.0 6.2 
104.5 38.0 41.2 10.9 77.1 8.1 
112.8 40.1 39.0 15.1 64.3 7.3 
IABP 75.6 38.0 48.9 11.7 48.0 3.6 
85.7 33.9 50.1 17.2 65.9 5.6 
97.1 37.6 50.8 14.8 61.7 6.0 
106.0 36.7 48.6 15.9 57.9 6.1 
114.1 36.2 48.8 18.3 64.2 7.3 
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Table 8 Stroke Volume = 50 ml 
Data 
Group 
HR 	 MASP 
(bt/min) 
	
(mmHg) 
MADP 
(mmHg) 
EDP 
(mmHg) 
SV 
(ml/bt) 
CO 
(L/min)  
Control 1 78.1 44.6 32.9 26.1 49.3 3.9 
(EABP) 87.2 53.1 38.7 33.3 52.2 4.6 
95.5 51.7 41.9 35.6 56.5 5.4 
106.0 51.0 42.8 36.0 49.6 5.3 
115.4 50.6 42.4 36.5 51.7 6.0 
Control 2 75.2 47.4 35.3 28.7 	 50.2 3.8 
(IABP) 86.5 48.7 35.4 28.4 51.7 4.5 
95.5 51.2 35.7 30.2 51.6 4.9 
106.8 52.2 42.0 36.1 54.1 5.8 
114.5 52.6 42.7 37.6 47.0 5.4 
EABP 80.4 37.6 45.2 5.6 96.5 7.8 
86.5 43.1 50.6 16.3 84.3 7.3 
95.5 45.8 49.3 23.4 91.0 8.7 
105.3 46.2 48.4 27.6 95.3 10.0 
115.8 46.5 46.7 29.6 81.5 9.4 
IABP 74.8 42.1 48.3 8.4 71.1 5.3 
87.5 38.2 48.7 13.0 54.9 4.8 
94.9 39.0 48.6 14.8 82.6 7.8 
105.6 42.9 54.3 23.5 70.1 7.4 
114.9 45.4 53.6 25.9 64.0 7.4 
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APPENDIX B 
Plots of Data vs. Heart Rate 
Figure 17 Mean Arterial Systolic Pressure 
vs. Heart Rate 
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Figure 18 Mean Arterial Diastolic Pressure 
vs. Heart Rate 
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Figure 19 End Diastolic Pressure 
vs. Heart Rate 
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Figure 20 Stroke Volume vs. Heart Rate 
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Figure 21 Cardiac Output vs. Heart Rate 
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